The influence of hormone therapy with drospirenone-estradiol on endometrioid type endometrial cancer patients.

J Gynecol Oncol 2018 Sep 4;29(5):e72. Epub 2018 May 4.

Department of Obstetrics and Gynecology, Kyung-Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, Seoul, Korea.

Objective: To determine whether drospirenone/estradiol (DRSP/E2) has an adverse effect on clinical outcomes in surgically staged International Federation of Gynecology and Obstetrics (FIGO) stage I/II endometrial cancer (EC) patients.

Methods: In a retrospective case-controlled study, 58 women with EC who had received DRSP/E2 postoperatively were compared with 116 women who had not. And, oncologic safety of postoperative hormone therapy with DRSP/E2 in EC survivors were compared between the 2 groups after propensity score matching using a logistic regression model.

Results: The median ages were 47.7 years and 53.6 years for the study and the control groups, respectively (p<0.001). The study group had similar parity (p=0.71), lower body mass index (p=0.03) and more premenopausal women (p<0.001) than the control group. The stages were completely matched. The grades (p=0.42), lymphovascular space invasion (p=0.23), preoperative cancer antigen 125 (CA 125) level (p=0.89), and hormone receptor status (p=0.07) were similar in both groups. The median tumor diameter was statistically larger in the study group than in the control group (p<0.001). Both group received similar adjuvant therapy (p=0.80). In the propensity matching, only hormone receptor status was significantly different (p=0.03). In the univariate analysis, only stage was significantly associated with disease-free survival (DFS) and there was no variable associated with overall survival (OS). And, there was no significant factor identified in multivariate analysis. The difference in the DFS (p=0.63) and in the OS (p=0.32) was not significant. The same results were obtained after propensity score matching.

Conclusion: Postoperative hormone therapy with DRSP/E2 in EC survivors did not increase recurrence or the death rate.

Download full-text PDF

Source
http://dx.doi.org/10.3802/jgo.2018.29.e72DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6078887PMC
September 2018
11 Reads

Publication Analysis

Top Keywords

hormone therapy
8
endometrial cancer
8
compared 116
4
postoperatively compared
4
drsp/e2 postoperatively
4
116 women
4
women oncologic
4
postoperative hormone
4
safety postoperative
4
oncologic safety
4
received drsp/e2
4
women received
4
stage i/ii
4
figo stage
4
obstetrics figo
4
i/ii endometrial
4
cancer patientsmethods
4
study women
4
case-controlled study
4
patientsmethods retrospective
4

Similar Publications